Mesoblast rises as Ryoncil sales climb 60% in December quarter
Source: SeekingAlpha
2026-01-09 13:01:10 ET
More on Mesoblast
- Mesoblast appoints James M. O’Brien as US-based CFO
- Seeking Alpha’s Quant Rating on Mesoblast
- Historical earnings data for Mesoblast
- Financial information for Mesoblast
Read the full article on Seeking Alpha
For further details see:
Mesoblast rises as Ryoncil sales climb 60% in December quarter
Mesoblast Limited
NASDAQ: MESO
MESO Trading
-3.57% G/L:
$15.13 Last:
97,266 Volume:
$15.19 Open:
MESO Latest News
March 03, 2026 10:02:00 am
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
MESO Stock Data
$2,320,216,937
94,873,961
N/A
31
N/A
Biotechnology & Life Sciences
Healthcare
AU
Melbourne
